Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Novartis pipeline in registration
Solid Tumors
Code
Name
Mechanism
Indication(s)
VDT482 tislelizumab
PD1 inhibitor
2L ESCC
Non-small cell lung cancer
Immunology
Code
Name
Mechanism
AIN457
Cosentyx®
IL17A inhibitor
IGE025
XolairⓇ
IgE inhibitor
1. Approved in EU.
Indication(s)
Hidradenitis suppurativa¹
Psoriatic arthritis (IV formulation)
Axial SpA (IV formulation)
Auto-injector
Appendix
Innovation: Clinical trials
Hematology
Code
LNP023
References
Abbreviations
INNOVATION
2 lead indications
Name
Mechanism
Indication(s)
iptacopan
CFB inhibitor
Paroxysmal nocturnal hemoglobinuria
Lead indication
35 Investor Relations | Q2 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation